MultiparametricMRI‐Based Radiomics Approaches for Preoperative Prediction ofEGFRMutation Status in Spinal Bone Metastases in Patients with Lung Adenocarcinoma
- 27 February 2021
- journal article
- research article
- Published by Wiley in Journal of Magnetic Resonance Imaging
- Vol. 54 (2) , 497-507
Abstract
Background: Preoperative prediction of epidermal growth factor receptor (EGFR) mutation status in patients with spinal bone metastases (SBM) from primary lung adenocarcinoma is potentially important for treatment decisions.Purpose: To develop and validate multiparametric magnetic resonance imaging (MRI)‐based radiomics methods for preoperative prediction of EGFR mutation based on MRI of SBM.Study Type: Retrospective.Population: A total of 97 preoperative patients with lumbar SBM from lung adenocarcinoma (77 in training set and 20 in validation set).Field Strength/Sequence: T1‐weighted, T2‐weighted, and T2‐weighted fat‐suppressed fast spin echo sequences at 3.0 T.Assessment: Radiomics handcrafted and deep learning‐based features were extracted and selected from each MRI sequence. The abilities of the features to predict EGFR mutation status were analyzed and compared. A radiomics nomogram was constructed integrating the selected features.Statistical Tests: The Mann‐WhitneyUtest and χ2test were employed for evaluating associations between clinical characteristics and EGFR mutation status for continuous and discrete variables, respectively. Least absolute shrinkage and selection operator was used for selection of predictive features. Sensitivity (SEN), specificity (SPE), and area under the receiver operating characteristic curve (AUC) were used to evaluate the ability of radiomics models to predict the EGFR mutation. Calibration and decision curve analysis (DCA) were performed to assess and validate nomogram results.Results: The radiomics signature comprised five handcrafted and one deep learning‐based features and achieved good performance for predicting EGFR mutation status, with AUCs of 0.891 (95% confidence interval [CI], 0.820–0.962, SEN = 0.913, SPE = 0.710) in the training group and 0.771 (95% CI, 0.551–0.991, SEN = 0.750, SPE = 0.875) in the validation group. DCA confirmed the potential clinical usefulness of the radiomics models.Data Conclusion: Multiparametric MRI‐based radiomics is potentially clinical valuable for predicting EGFR mutation status in patients with SBM from lung adenocarcinoma.Level of Evidence: 3Technical Efficacy: 2Keywords
This publication has 37 references indexed in Scilit:
- Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approachNature Communications, 2014
- The Incidence of EGFR-Activating Mutations in Bone Metastases of Lung AdenocarcinomaPathology and Oncology Research, 2013
- Oncogenic Pathways, Molecularly Targeted Therapies, and Highlighted Clinical Trials in Non–Small-Cell Lung Cancer (NSCLC)Clinical Lung Cancer, 2012
- Nomogram to predict the presence ofEGFRactivating mutation in lung adenocarcinomaEuropean Respiratory Journal, 2011
- Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practiceJournal of Experimental & Clinical Cancer Research, 2011
- Bone metastasis: mechanisms and therapeutic opportunitiesNature Reviews Endocrinology, 2011
- Youden Index and Optimal Cut‐Point Estimated from Observations Affected by a Lower Limit of DetectionBiometrical Journal, 2008
- Selection of important variables and determination of functional form for continuous predictors in multivariable model buildingStatistics in Medicine, 2007
- Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or ErlotinibClinical Cancer Research, 2006
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004